Faes Farma
↗Leioa, Spain
Faes Farma is a Spanish pharmaceutical company founded in 1933, specializing in the research, development, manufacturing, and marketing of prescription drugs, healthcare products, and animal nutrition and health solutions. The company operates globally with a presence in over 130 countries, maintaining a strong focus on innovation through its R&D centers in Spain.
The group is organized into two main business areas: Pharma & Healthcare and FARM Faes (Animal Nutrition and Health). Recent strategic growth has been driven by international expansion and acquisitions, notably the 2025 integration of SIFI (ophthalmology) and Laboratorios Edol, significantly strengthening its ophthalmic franchise.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Allergy, Gastrointestinal, Ophthalmology, Bone Metabolism
SIZE & FINANCIALS
Employees:1001-5000
Revenue:$500M-$1B
Founded:1933
Ownership:public
Status:operating
STOCK
Exchange:Bolsa de Madrid
Ticker:FAE
PIPELINE
Stage:Phase 3
Lead Drug Stage:Commercial
Modalities:Small molecule
Active Trials:28
Trial Phases:-
FDA Approvals:0
EMA Approvals:1
CORPORATE STRUCTURE
Subsidiaries:Laboratorios Vitoria, SIFI, Laboratorios Edol, Ingaso Farm, Tecnovit, Capselos
Key Partnerships:Menarini (Bilastine commercialization), GSK (Bilastine commercialization)
COMPETITION
Position:Leader
Competitors:Almirall, Grifols, Laboratorios Cinfa
LEADERSHIP
Key Executives:
Eduardo Recoder de la Cuadra - CEO
LINKS
Website:faes.es
LinkedIn:LinkedIn Profile
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Faes Farma and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Faes Farma. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.